Stay updated on Durvalumab in Resectable Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.

Latest updates to the Durvalumab in Resectable Lung Cancer Clinical Trial page
- Check7 days agoChange DetectedA new study-record version dated October 12, 2026, was added with changes spanning study status and design, outcome measures, and results and adverse events. Its quality-control review has not concluded, and it was returned on November 2, 2026.SummaryDifference0.5%

- Check14 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check21 days agoChange DetectedA site-wide NIH announcement says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference0.4%

- Check28 days agoChange DetectedThe site revision label changed from v3.7.1 to v3.7.2; the study record content remains unchanged.SummaryDifference0.1%

- Check35 days agoChange DetectedThe website footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision marker at the bottom of the page has been updated from v3.6.6 to v3.7.0, reflecting a recent system/UI update to the study history view. This change does not modify any study data or visible content beyond version labeling.SummaryDifference0.1%

Stay in the know with updates to Durvalumab in Resectable Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.